Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Moving upstream in anticancer drug development.
Journal: Nature reviews. Drug discovery
Published: March 13, 2019
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Journal: The Lancet. Oncology
Published: July 21, 2016
Disease Interception: Myths, Mountains, and Mole Hills.
Journal: Cancer prevention research (Philadelphia, Pa.)
Published: February 15, 2016
Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 25, 2014
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 09, 2013
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
Journal: The New England journal of medicine
Published: October 02, 2012
(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 24, 2012
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.
Journal: Lancet (London, England)
Published: May 22, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026